Try our Advanced Search for more refined results
Life Sciences - April, 2016
339 articles
- Gilead OK'd To Show Merck Atty Lied In $200M Patent Win
- J&J Baby Powder Cancer Suit Goes To Missouri Jury
- Drug Firms Battle In Del., Calif. Over Shared LLC, $60M IP
- Pfizer Still Can't Compare Children's Advil To Tylenol In Ads
- NuVasive Can't Erase $28M Verdict, Former Distributor Says
- GSK Seeks To Ax Heart Attack Suit In Diabetes Drug MDL
- Cubicin Patent Axing Doesn't Warrant Review, Justices Told
- OPINION: Engaging The Media May Help Your Client
- ITC Finds Imported Dental Implants Flouted Nobel Patents
- 4 Firms Set To Launch Biotech IPOs That Could Raise $185M
- Pharma CEO Hid FDA Hold From Investors, Jury Finds
- Hollister, Byram To Pay $21M In FCA Kickbacks Case
- After Rejection, Sanofi Threatens Hostile Bid For Medivation
- Brand Battles: Dentons, J&J, University of Texas
- Deals Rumor Mill: Yahoo, Pfizer, Atlante
- Reckitt Must Pay $1.3M For Putting Different Labels On Drug
- Taxation With Representation: Baker & McKenzie, Gibson Dunn
- FDA Greenlights Quest Diagnostics' Zika Test
- Merck Defeats NJ Town's Bid To Check Land Development
- Colo. Credit Union Says KC Fed Can't Enforce Pot Laws
- Mylan, Ranbaxy Push 3rd Circ. To Nix Provigil Class
- FDA To Mull Mandatory Opioid Education For Prescribers
- Alere Refuses Abbott Bid To Back Out Of $5.8B Merger
- Portfolios With 4 Legs To Stand On: Animal Drug Patent Tips
- High Court May Be Next Stop For PTAB Deference Issue
- Pharma CEO Says He's An Honest Guy As SEC Trial Wraps
- Abbott's Cardio-Focused $25B Deal Could Raise FTC's Pulse
- Pharmacies Say Express Scripts Conspiracy Suit Has Legs
- KaloBios Gets Final Nod On 'Unusual' $3M Ch. 11 Package
- FDA Flouting Court On Orphan Drug Exclusivity, Suit Says
- 3 Big Plays Make Noise In Muted Health Care M&A Market
- Old Spice Deodorant Causes Rashes, Class Action Claims
- Merck Says Gilead Is Exploiting Atty 'Lie' In $200M Jury Loss
- Sanofi Leans On Biopharm Firm Medivation To Take $9.3B Bid
- AbbVie Inks $5.8B Deal For Cancer Drug Maker Stemcentrx
- Using The New Federal Rules To Rein In Discovery
- Why Celebrity Sponsors Aren't Liable For False Advertising
- Dentons: A New Kind Of Network?
- Wachtell Steers Abbott In $25B Deal For St. Jude Medical
- 22 Firms Win Top Marks From GCs On AFAs
- Crede Blasts Tobacco Co. In $250M Suit Over China JV
- Chancery Suit Targets Fee-Shifting Bylaw Enacted Before Ban
- IRS Inversion Regs Don't Solve Tax Code Issues, Rep. Says
- Valeant CEO Says He Was 'Too Aggressive' On Drug Prices
- Abbott Urges Judge To Keep RICO Claims In Test Strip Row
- Female Merck Workers Get Cert. In Sex Bias Suit
- Amgen Urges Ban On Cholesterol Drug Sales After Patent Win
- FTC Settles Monopoly Case With Medical Polymer Co. Invibio
- Fed. Circ. Won't Rehear Howmedica Polymer Patent Appeal
- 4th Circ. Affirms Toss Of Utah Woman's Vaginal Mesh Suit
- FDA Accused Of Hiding Details On Its Advisers
- Philly Paxil Litigation Paused During Fight Over Initial Case
- Amarin Again Dodges Securities Suit Over Vascepa Denial
- Olympus Expands Global Team With GC, Compliance Officer
- CVS Hits Back At Texas In 1st Circ. Medicaid Drug FCA Row
- What's The Big Deal About US Biosimilar Approval?
- 4th Circ. Revives FCA Suit Over Pfizer Pain Patch
- Lupin Wins Feds' OK Of Settlement In $850M Gavis Buy
- The Firms That Handle The Most ANDA Patent Cases
- Endo Loses DQ Bid In Consumer Suit Over Fluoride Labeling
- More Details Emerge Of Lab Practices At Theranos
- Fed. Circ. Keeps Deference For PTAB, Despite Misgivings
- Stryker Unit Slams DJO Over Worker Poaching Scheme
- FDA Mulls Study On Yeast Infection Drug's Miscarriage Risk
- Allergan, Others Hit With Generic Drug Price-Fixing Suit
- NY Insurers Agree To Provide Costly Hep C Treatments
- 1st Meningitis Bellwether Trial Pushed Back To August
- FDA Warning Wire: Drug Ratings Nixed By Suspect Tests
- Takeda, Blackfeet Member Ask 9th Circ. To Call Off Actos Suit
- What To Know About Trade Secret Law In Saudi Arabia
- Risk Of Future Misconduct Will Guide HHS Investigations
- Pfizer Accuses Lipitor Users Of Forum-Shopping In MDL
- Bard Ends Several Dozen Pelvic Mesh Suits In MDL
- GNC Slammed For 'Sham' Online Pricing Scheme
- 9th Circ. Won't Revive Wal-Mart Migraine Drug Price Suit
- Insurers, Hospitals Float Ideas To Curb Drug Spending
- Chiesa Shahinian Nabs 6 Herrick Feinstein LLP Attys
- Deals Rumor Mill: Novartis, Honeywell, KRG Capital
- Lowenstein Sandler Snags Ex-Mintz Levin Corporate Atty
- Biopharm Co. Says AstraZeneca Lifted Data, Seeks $33.8M
- IKOR Founder Seeks To Undo $5M Investment Breach Verdict
- Valeant Taps Perrigo CEO To Right Ship
- Quo Vadis FTC?: The Meaning Of FTC Case Against Endo
- The D&O Policy Implications Of SEC's Theranos Probe
- Pa. Justices Urged To Affirm $4.8M Asbestos Verdicts
- Health Hires: Akin Gump Gets A Fed, Morris Manning An IP Pro
- Jury Awards Concordia Pharma $730K In False Ad Row
- FDA Eyes Ban On Electric Shock For Violent Behavior
- Nixon Peabody Says Intel's Tapped Out In Biotech Stock Row
- First Mirena IUD Cases Dropped; Bayer Cites Lack of Experts
- Ex-Covidien Sales Manager Loses Age Bias Dispute
- Snooki, Diet Pill Co.'s False Ad Appeal Pointless, Group Says
- Benefits Of Expedited Review Of Sole-Source Drug ANDAs
- 4 Reasons Nonpharma Attys Should Know Pay-For-Delay Law
- Avoiding The Pitfalls Of Researching Attorneys In PACER
- Stock Tipper Can't Ax SEC Deal After Newman, 3rd Circ. Told
- FDA Rejects Surgical Robot From TransEnterix
- SEC Gets Injunction Against Ski Resort And CEO In EB-5 Suit
- Deals Rumor Mill: Vodafone, CMA CGM, Concordia Healthcare
- A Review Of Gov't Cases Against Execs In Q1
- PE-Backed American Renal Prices $165M IPO Near Peak Range
- IBio Settles Investor Suit Over Ebola Drug Plans For $1.87M
- FedEx Can't Duck Money Laundering Counts In Drug Case
- New Tax Plan Will Hurt IT, Pharma Vendors In Texas
- State Legislation Vs. Federal Prohibition Of Marijuana
- Dow Can't Pause Fed. Circ. Appeal Of $456M Bayer Award
- Sandoz Loses Bid To Invalidate IP In Toviaz Row With Pfizer
- Patents 'Decimated' By Eligibility Rulings, Justices Told
- Reckitt Ducks Drug Supply Order In Mucinex Antitrust Case
- Biotech Entrepreneur, Others Want OxyContin Case Reheard
- Drug Labels Must Reflect Risk Sooner, Tylenol Court Told
- 9th Circ. Vacates $2.3M Fee Award In Nobel Implant Row
- Del. Chief Justice Asks If 'Liars' Set Up $16M Stock Fault
- Supplement Buyers Push To Keep False Ad Class Action Alive
- Abbott CEO Silent On $5.8B Alere Deal Amid FCPA Scrutiny
- Pillsbury Nabs Ex-Sterne Kessler IP, Pharma Pro In DC
- Intuitive Cuts Deal Before Jury Verdict In $30M Robot Trial
- Resort Owner Says SEC Can Only Freeze $50M In EB-5 Suit
- IRS Says Colorado Pot Dispensary Can't Deduct Expenses
- Economics Of Harm From Biologic-Biosimilar Competition
- 2nd Circ.'s Application Of Janus Is Noteworthy
- SEC's Theranos Probe Shows Unicorn Hunt Not A Myth
- Express Scripts Countersues Anthem Amid $13B Suit
- Endo, Others Denied Wholesale Info In Pay-For-Delay MDL
- FDA Warning Wire: Coin Tosses, Raw Dog Food, Drug Gels
- Texas Slams CVS Stores In 1st Circ. Medicaid Drug Row
- FedEx Can't Dodge Prescription Drug Shipping Indictment
- J&J Loses Bids To Limit Testimony In Tylenol Bellwether
- GSK, Others Appeal UK Watchdog's Pay-For-Delay Penalties
- Celltrion Rips Janssen's Bid to Move Up Biosimilar Trial Date
- Apotex Says Mylan, Ranbaxy Rewrite Law In Provigil Appeal
- Mylan Says Fed. Circ. Jurisdiction Rule Unfair To Generic Cos.
- Immunosyn CEO Hid FDA Hold From Investors, Jury Told
- 3 Life Science Cos. Bolster IPO Pipeline With $101M In Deals
- Novartis Asks 3rd Circ. To Uphold Dismissal Of Zometa Suit
- Bellwether Trials: A Defense Perspective
- Interpreting A Patent Is Not So 'Plain And Ordinary' After All
- CytRx Using Forum Flip-Flop To Stall Del. Case, Investors Say
- Spending Bill Pushes FDA Approval Of Drug Label Changes
- Eli Lilly, Elan Get $8M In Fees After Alzheimer's IP Win
- Benicar MDL Cases Survive Daiichi's Symptom Challenges
- ConforMIS Investors Fight Bid To Toss Suit Over $140M IPO
- AstraZeneca, Ranbaxy Ask 1st Circ. To Affirm Nexium Win
- Theranos Under Investigation By SEC, US Attorney's Office
- Generics Group Decries 'Troubling' AbbVie Biosimilars Petition
- Wis. Tribe Pushes For Hemp Crop OK Over DEA Objections
- Deals Rumor Mill: AstraZeneca, Ardagh Group, Yahoo
- Drug Cos. Wants Chicago Opioid Suit Paused For FDA Results
- FTC, Supplement Co. Request Stay In False Ad Suit
- Investors Say KaloBios Doesn't Need $3M DIP Loan
- Littler Lures Jackson Lewis Employment Pro In Miami
- Another Take On Reed Smith, Pepper Hamilton Merger Talks
- Bristol-Myers Ruling Highlights Biologics Patent Eligibility
- The Best Law Firms For Female Partners
- The Glass Ceiling Report
- The Top 5 Ways BigLaw Is Failing Women
- The 100 Best Law Firms For Female Attorneys
- Sanofi Says Amgen Patents Doomed Despite Jury Win
- Ex-Morgan Stanley Exec's CPA Gets 1 Day For Trading Tips
- 7th Circ. Won't Revive IP Suit Over Amylin Drug Promos
- 3 Takeaways From FDA's Drug Compounding Guidances
- AbbVie Wants MedImmune's Humira Patent Invalidated
- Pom Ruling Controls Diet Drugs False Ad Claims: 9th Circ.
- Insurer Sues Over Defense Costs For Meningitis Suits
- Honigman Adds Simpson Thacher, Kirkland, Ropes Attys
- Takeda Slams FDA Approval Of Rival's Gout Drug At DC Circ.
- GenSight Pulls $65M IPO, 2nd Biotech To Do So This Week
- Pa. Judge Urged To Revive Paxil Case After Midtrial Ax
- Buyers Urge 3rd Circ. To Reopen Effexor Pay-For-Delay Suit
- AbbVie Retires Cholesterol Drugs Amid Risk-Benefit Doubts
- Deals Rumor Mill: MBK Partners, Gland Pharma, AC Milan
- Bristol-Myers Expands Bay Area Research Footprint
- 10 Things To Know About US Biosimilar Reimbursement
- J&J Unit Settles Ex-Exec's Whistleblower Claims In NJ
- OPINION: Advising The GOP About Its Obligation To Advise
- Proposed Theranos CEO Ban Ups Ante For Lab Testing Cos.
- Industry Outpaces Gov't Agencies On Cybersecurity: Report
- FDA Data Integrity Guide Ends Excuses For Suspect Records
- 3rd Circ. Urged To Reverse Ruling In Merck Fraud Row
- 11th Circ. Urged To Revive Med. Supplier's Malpractice Row
- S&P Lowers Valeant Credit Rating After Delayed SEC Filing
- PTAB Rejects AIA Challenge To Amgen Drug Patent
- SEC Accuses Ski Resort Owner, CEO Of $350M EB-5 Fraud
- Philly Cancer Center Says Licensee Broke Agreement
- China Retreats On Subsidies To Settle US WTO Case
- Trade Secret Pitfalls For The Hatch-Waxman Litigant
- IRS Settlement With Carmex Owners Is Surprising
- Walgreens Urges 3rd Circ. To Keep Provigil Class Certified
- Feds Float 2-Year Ban On Theranos CEO Holmes
- Health Care, Addiction Experts Want Opioid Rules Changed
- Biotech Co. Says Brewer's Kombucha Teas Infringe Its IP
- Deals Rumor Mill: Lonza Group, IDT, Deutsche Bank
- J&J Baby Powder Caused Ovarian Cancer, Jury Told
- Health Care-Focused PE Firm Surpasses $150M For New Fund
- Jury To Decide If J&J Fired Exec For Affair Or Whistlebowing
- Janssen Seeks Patent Trial To Halt Celltrion Biosimilar
- PTAB Can Institute AIA Reviews, USPTO Tells Fed. Circ.
- UK Fines Pfizer For Missed Deadline In Epilepsy Med Probe
- Prescription Drug Oversight Bill Headed To President
- Valeant CEO Will Testify About Drug Prices Before Senate
- Can The Life Sciences Industry Bank On Biosimilars?
- Trans Ova Gets Part Of Verdict Axed In Sex-Selection IP Row
- CVS Shoppers Ask 1st Circ. To Reverse Vitamin E Label Ruling
- Valeant Faces Default Amid Looming Debt
- FDA Panel Delays Approval Of Clovis' Lung Cancer Drug
- Valeant CEO Obstructing Drug Price Probe, Lawmaker Says
- Redskins Blast Government's Flanax Claim As 'Ironic'
- Health Cos. Settle FTC's 'All Natural' False Ad Claims
- House Agrees To Priority FDA Review For Zika Treatments
- Deals Rumor Mill: Chevron, Gryphon Investors, Tipico
- Parents Asks Justices To Up Standard In Vaccine Act Row
- VC-Backed Biotech, Midsize Bank Boost Growing IPO Pipeline
- Kappos Calls For Abolition Of Section 101 Of Patent Act
- Chinese Anti-Bribery Law May Be Changing
- FDA Warning Wire: Hospital In Mayo Clinic Network Scolded
- Fed. Circ. Affirms Nixing Of Bayer Contraceptive Patent
- How To Align APEC And EU Cross-Border Transfer Rules
- Forbion Capital Closes $208M Life Sciences Fund
- 2nd Circ. Revives Pfizer Securities Suit Over Drug Risks
- J&J Ultamet Verdict Is Too Much Green
- Hogan Lovells Adds Corporate Trio From Pepper Hamilton
- Boston Scientific Recalls Catheters Over Breakage Risk
- Diet Pill Co., Snooki Want 2nd Circ. Input In False Ad Suit
- Valeant Board Urges CEO To Show For Senate Deposition
- Bone Stimulator Co. Beats FCA Doc-Coaching Suit
- Man Asks 9th Circ. To Recertify 'Sexual Energy' False Ad Class
- NY Human Tissue Co. Escapes Body Parts Harvesting Suit
- Foley Hoag Nabs Capital Markets Pro From Locke Lord
- Wi-Fi Band Expansion May Harm Hearing Aids, FCC Warned
- GNC Agrees To Pay $9M To End Calif. Labor, Wage Class Suit
- Label Suit Should Be Erased, Drugmakers Tell NJ Judges
- KaloBios Vows No Predatory Drug Pricing After Bankruptcy
- PE-Backed AdvancePierre Leads 3 New Filings With $100M IPO
- Endo, Impax Move To Trim Opana Pay-For-Delay MDL
- The Role Of Section 271(g) In The Wake Of ClearCorrect
- Watch Out: SEC Is Watching Your Dealings With Regulators
- Recovery From Q1 IPO Slump Could Take Years
- Abbott Can't Escape Punitive Damage Claim In Depakote Suit
- FDA Staff Not Convinced Of Clovis Cancer Drug Safety
- LD Vision Tells 10th Circ. Utah Is Blind To Lens Price Law
- Health Fraud Defense Attys Riding High As Wins Pile Up
- NJ Justices To Weigh Generic Reglan Preemption Claims
- Fed. Circ. Rules That Mayo Dooms Gene Detection Patent
- KaloBios Pharmaceuticals Files Renewed Ch. 11 Plan
- Health Hires: DLA Piper, King & Spalding Expand FDA Groups
- Mom Appeals Depakote Birth Defect Ruling To Sixth Circuit
- Fed. Circ. Won't Revive OxyContin Anti-Abuse Patent
- Nixon Peabody Can't Dodge Stock Fee Queries, Biotech Says
- Feds Say Flanax TM Ruling Bolsters Case Against Redskins
- Cold Spring RNA Patents Withstand AIA Challenge
- $200M Suture Antitrust Suit Nixed For Lack Of Market Power
- FDA Takes First Step To Remove Swine Drug From Market
- Legal Delivery In The 'Gig Economy'
- Proposed FDA Powdered Glove Ban: Effect On Device Makers
- Rising Star: Beasley Allen's Danielle Mason
- Ex-Access CEO Can't Now Claim Substance Abuse
- Adderall Buyers Seek Approval Of $15M Pay-For-Delay Deal
- DEA Mulling Whether To Reclassify Marijuana
- Theranos Boosts Board With MDs Amid Blood Test Spat
- FTC Wins Order Barring Japan Drug Co. From Generics Deals
- Fed. Circ. Sets New IP Trial Over J&J Expert's False Claims
- Rising Star: Ropes & Gray's Joy Liu
- Novartis, Feds Ordered To Hash Out Kickbacks Discovery
- Abbott Prevails In $219M Whistleblower FCA Trial
- PTAB Ruling Used New Arguments, Genzyme Tells Fed. Circ.
- J&J Must Face Cherokee Risperdal Suit In State Court
- Ex-Abbott Rep Says Profits Trumped Safety In $219M FCA Trial
- 6 Takeaways From Novartis FCPA Case
- Sanofi Can't Escape Junk Fax Suit After Campbell-Ewald
- Medtronic Wins FDA Approval For First Wireless Pacemaker
- Rising Star: Davis Polk's Sophia Hudson
- Ex-Morgan Stanley VP Gets 1 Day In Prison For Sanofi Scam
- Construction's $2.6B In Claims Easily Tops At AAA In 2015
- Texas Medical Equipment Co. Owners Charged With Fraud
- Nixed Pfizer Inversion Casts Uncertainty On Similar Deals
- FDA Calls Retroactive Exclusivity Unfair To Generics Makers
- BioPharma Services Provider InVentiv Files $100M IPO
- Antitrust Rule Of Reason Cases Tough To Try, Judges Say
- Wright Gets Damages Cut After First Hip Implant MDL Trial
- CVS, Rite Aid Hit Warner Chilcott With Loestrin Antitrust Suit
- Sweeping Medical Innovation Bill Nears Senate Vote
- 5 Best FDA Warning Letter Practices For Attorneys
- Pfizer, Allergan End $160B Merger After New Inversion Regs
- Pfizer Prevails In Zoloft Birth Defect MDL
- Excluded Evidence Could Revive Pa. Paxil Case On Appeal
- KaloBios Seeks End To Investor Suit To Clear Ch. 11 Plan
- Inversion Regs Cast Net Wider Than Pfizer-Allergan Deal
- Hospira Can't Shake Patent Row Over Generic Aloxi
- Wal-Mart's High-Cost Migraine Drug Misled, 9th Circ. Told
- Creative Solutions Needed To Pass TPP, Ex-USTR Official Says
- Ex-CEO Wants Stay In Former Oriole's Insider Trading Suit
- Sens. Introduce Bill To Protect Genetic Information
- Travelers Denied Win In Row Over Becton's $167M In Deals
- Deals Rumor Mill: Pfizer, Halliburton, Siemens
- Purdue Asks Fed. Circ. To Revive Anti-Abuse OxyContin IP
- Bayer Urges Fed Circ. To Reinstate Contraceptive Patent
- Eli Lilly Urges Justices To Rethink Patent-Eligibility Test
- FDA Backs Celltrion Biosimilar Of Janssen's Remicade
- FDA Warning Wire: Lice Lotion, Dirty Cheese, Workout Pills
- Health Network Wants Bellwethers Paused In Meningitis MDL
- Rising Star: Kaye Scholer's Aaron Gardner
- FDA Panel Outlines Hub For Medical Device Data
- GSK, Teva Pick Up Steam In Lamictal Pay-For-Delay Cert Bid
- 2nd Circ. Eyes BMS $30M Suit Over Mylan's Sale Of AIDS Drug
- Cubist Turns To Supreme Court In Antibiotic Patent Case
- Drugmaker SIGA Wins Approval Of Ch. 11 Plan
- FTC Amicus Brief Highlights Post-Actavis Challenges
- Lay And Expert Testimony: Using Employee Witnesses
- Ex-MedImmune Exec Can't End SEC's Ban After Settlement
- IRS Can Collect From Supplement Co., Tax Court Says
- Feds Trim Pay Boost For Medicare Advantage In 2017
- Rising Star: Dechert's Tony Chan
- J&J Witness Tells Jury Fired Exec Pursued Her
- 9th Circ. Revives Trade-Dress Claim Over Medical Reports
- Foley Picks Up IP Partner From Hogan Lovells In Japan
- Jury Finds Tyco Not Liable In $60M Drug Heist Trial
- Suture To Take $200M Antitrust Suit Dismissal To 10th Circ.
- Zimmer Wants Sanctions For Axed Suit In Knee Implant MDL
- Boston Scientific Testing Surgical Mesh For Fake Parts: FDA
- Biosimilar Notice Rule Isn't Absolute, Apotex Tells Fed. Circ.
- GSK Scores Midtrial Dismissal Of Paxil Birth Defect Suit
- UC Prof Fudged Painkiller Data, Drugmaker Alleges
- Mexican Official: Not Much Wiggle Room On Biologics In TPP
- 7 Lessons I Learned As A Trial Lawyer On Jury Duty
- Say It Ain't So: Fed. Circ. Denies ClearCorrect Rehearing
- Girardi Keese Hoarding $4.4M In Atty Fees, Co-Counsel Says
- Shkreli Says No Direct Infringement Of Wu-Tang Album Art
- Abbott Can't Duck Depakote Failure-To-Warn Birth Defect Suit
- NAM Urges Justices To Take Up Lamictal Pay-For-Delay Case
- Life Sciences IPOs Edge 1 Firm Ahead Of Peers In Quiet March
- Abbott Whistleblower Blasts Directed Verdict Bid
- Diet Pill Maker, Snooki Can't Ax Weight Loss False Ad Suit
- Rising Star: Quinn Emanuel's Andrew Chalson
- FTC Wins Restrictions On Lifewatch's Telemarketing
- Silver Lake Investment Values Ancestry.com At $2.6B
- Universities Protest House Panel's Fetal Tissue Subpoenas
- The 2016 Rising Stars, By Firm
- Insurer Urges Denial Of Directed Verdict In $60M Heist Suit
- Viewing Recent Opioid Regulations In Context